{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:00:19Z","timestamp":1793149219061,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["75N93021D00014"],"award-info":[{"award-number":["75N93021D00014"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"DOI":"10.1186\/s12866-025-04196-w","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T03:44:01Z","timestamp":1753847041000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Establishing translational performance standards for TB therapy using rifampicin-based regimens in a male and female high-burden murine model"],"prefix":"10.1186","volume":"25","author":[{"given":"Jason E.","family":"Cummings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Woolhiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory T.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Nurul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Slayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"issue":"5","key":"4196_CR1","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/nrd4001","volume":"12","author":"A Zumla","year":"2013","unstructured":"Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov. 2013;12(5):388\u2013404. https:\/\/doi.org\/10.1038\/nrd4001.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"4196_CR2","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1056\/NEJMoa2212537","volume":"388","author":"NI Paton","year":"2023","unstructured":"Paton NI, Cousins C, Suresh C, Burhan E, Chew KL, Dalay VB, et al. Treatment strategy for Rifampin-Susceptible tuberculosis. N Engl J Med. 2023;388(10):873\u201387. https:\/\/doi.org\/10.1056\/NEJMoa2212537.","journal-title":"N Engl J Med"},{"issue":"11","key":"4196_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41579-022-00731-y","volume":"20","author":"VA Dartois","year":"2022","unstructured":"Dartois VA, Rubin EJ. Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nat Rev Microbiol. 2022;20(11):685\u2013701. https:\/\/doi.org\/10.1038\/s41579-022-00731-y.","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"4196_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0041-3879(85)90040-6","volume":"66","author":"DA Mitchison","year":"1985","unstructured":"Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle. 1985;66(3):219\u201325. https:\/\/doi.org\/10.1016\/0041-3879(85)90040-6.","journal-title":"Tubercle"},{"key":"4196_CR5","doi-asserted-by":"publisher","unstructured":"Zohaib Ali M, Dutt TS, MacNeill A, Walz A, Pearce C, Lam H, et al. A modified BPaL regimen for tuberculosis treatment replaces linezolid with inhaled spectinamides. Elife. 2024;13. https:\/\/doi.org\/10.7554\/eLife.96190.","DOI":"10.7554\/eLife.96190"},{"issue":"11","key":"4196_CR6","doi-asserted-by":"publisher","first-page":"e0071624","DOI":"10.1128\/aac.00716-24","volume":"68","author":"AA Bauman","year":"2024","unstructured":"Bauman AA, Sarathy JP, Kaya F, Massoudi LM, Scherman MS, Hastings C, et al. Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis. Antimicrob Agents Chemother. 2024;68(11):e0071624. https:\/\/doi.org\/10.1128\/aac.00716-24.","journal-title":"Antimicrob Agents Chemother"},{"key":"4196_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/978-3-031-35139-6_6","volume":"441","author":"D Dabitao","year":"2023","unstructured":"Dabitao D, Bishai WR. Sex and gender differences in tuberculosis pathogenesis and treatment outcomes. Curr Top Microbiol Immunol. 2023;441:139\u201383. https:\/\/doi.org\/10.1007\/978-3-031-35139-6_6.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"2","key":"4196_CR8","first-page":"194","volume":"8","author":"AC Crampin","year":"2004","unstructured":"Crampin AC, Glynn JR, Floyd S, Malema SS, Mwinuka VK, Ngwira BM, et al. Tuberculosis and gender: exploring the patterns in a case control study in Malawi. Int J Tuberc Lung Dis. 2004;8(2):194\u2013203.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"4196_CR9","doi-asserted-by":"publisher","first-page":"7695","DOI":"10.1038\/s41598-024-58080-0","volume":"14","author":"LW Limenh","year":"2024","unstructured":"Limenh LW, Kasahun AE, Sendekie AK, Seid AM, Mitku ML, Fenta ET, et al. Tuberculosis treatment outcomes and associated factors among tuberculosis patients treated at healthcare facilities of Motta town, Northwest ethiopia: a five-year retrospective study. Sci Rep. 2024;14(1):7695. https:\/\/doi.org\/10.1038\/s41598-024-58080-0.","journal-title":"Sci Rep"},{"issue":"1","key":"4196_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12916-018-1169-5","volume":"16","author":"ME Murphy","year":"2018","unstructured":"Murphy ME, Wills GH, Murthy S, Louw C, Bateson ALC, Hunt RD, et al. Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the remoxtb study. BMC Med. 2018;16(1):189. https:\/\/doi.org\/10.1186\/s12916-018-1169-5.","journal-title":"BMC Med"},{"issue":"9","key":"4196_CR11","doi-asserted-by":"publisher","first-page":"e1002119","DOI":"10.1371\/journal.pmed.1002119","volume":"13","author":"KC Horton","year":"2016","unstructured":"Horton KC, MacPherson P, Houben RM, White RG, Corbett EL. Sex differences in tuberculosis burden and notifications in Low- and Middle-Income countries: A systematic review and Meta-analysis. PLoS Med. 2016;13(9):e1002119. https:\/\/doi.org\/10.1371\/journal.pmed.1002119.","journal-title":"PLoS Med"},{"issue":"5","key":"4196_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1046\/j.1365-2710.1999.00246.x","volume":"24","author":"E Tanaka","year":"1999","unstructured":"Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther. 1999;24(5):339\u201346. https:\/\/doi.org\/10.1046\/j.1365-2710.1999.00246.x.","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"4196_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2165\/11598930-000000000-00000","volume":"51","author":"SC McLeay","year":"2012","unstructured":"McLeay SC, Morrish GA, Kirkpatrick CM, Green B. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet. 2012;51(5):319\u201330. https:\/\/doi.org\/10.2165\/11598930-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"4196_CR14","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.chest.2022.09.024","volume":"163","author":"S Deshmukh","year":"2023","unstructured":"Deshmukh S, Sane M, Gaikwad S, Sahasrabudhe T, Barthwal M, Lokhande R, et al. Sex differences in TB clinical presentation, drug exposure, and treatment outcomes in India. Chest. 2023;163(4):778\u201389. https:\/\/doi.org\/10.1016\/j.chest.2022.09.024.","journal-title":"Chest"},{"key":"4196_CR15","doi-asserted-by":"publisher","unstructured":"Pontali E, Raviglione MC, Migliori GB, the writing group members of the Global TBNCTC. Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives. Eur Respir Rev. 2019;28(152). https:\/\/doi.org\/10.1183\/16000617.0035-2019.","DOI":"10.1183\/16000617.0035-2019"},{"issue":"8","key":"4196_CR16","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1128\/AAC.00912-12","volume":"56","author":"IM Rosenthal","year":"2012","unstructured":"Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, et al. Dose-ranging comparison of Rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother. 2012;56(8):4331\u201340. https:\/\/doi.org\/10.1128\/AAC.00912-12.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"4196_CR17","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1128\/AAC.02565-14","volume":"58","author":"SM Irwin","year":"2014","unstructured":"Irwin SM, Gruppo V, Brooks E, Gilliland J, Scherman M, Reichlen MJ, et al. Limited activity of Clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas. Antimicrob Agents Chemother. 2014;58(7):4026\u201334. https:\/\/doi.org\/10.1128\/AAC.02565-14.","journal-title":"Antimicrob Agents Chemother"},{"issue":"18","key":"4196_CR18","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","volume":"384","author":"SE Dorman","year":"2021","unstructured":"Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, et al. Four-Month rifapentine regimens with or without Moxifloxacin for tuberculosis. N Engl J Med. 2021;384(18):1705\u201318. https:\/\/doi.org\/10.1056\/NEJMoa2033400.","journal-title":"N Engl J Med"},{"key":"4196_CR19","doi-asserted-by":"publisher","unstructured":"Larkins-Ford J, Greenstein T, Van N, Degefu YN, Olson MC, Sokolov A et al. Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis. Cell Syst. 2021;12(11):1046-63 e7; https:\/\/doi.org\/10.1016\/j.cels.2021.08.004","DOI":"10.1016\/j.cels.2021.08.004"},{"issue":"12","key":"4196_CR20","doi-asserted-by":"publisher","first-page":"6166","DOI":"10.4049\/jimmunol.164.12.6166","volume":"164","author":"CD Mills","year":"2000","unstructured":"Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1\/M-2 macrophages and the Th1\/Th2 paradigm. J Immunol. 2000;164(12):6166\u201373. https:\/\/doi.org\/10.4049\/jimmunol.164.12.6166.","journal-title":"J Immunol"},{"issue":"5","key":"4196_CR21","doi-asserted-by":"publisher","first-page":"456","DOI":"10.4103\/ijmr.IJMR_554_18","volume":"147","author":"AK Singh","year":"2018","unstructured":"Singh AK, Gupta UD. Animal models of tuberculosis: lesson learnt. Indian J Med Res. 2018;147(5):456\u201363. https:\/\/doi.org\/10.4103\/ijmr.IJMR_554_18.","journal-title":"Indian J Med Res"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-04196-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-025-04196-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-04196-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T04:06:04Z","timestamp":1753934764000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-025-04196-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4196"],"URL":"https:\/\/doi.org\/10.1186\/s12866-025-04196-w","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All vertebrate animal use at Colorado State University is conducted under Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) approval and has an Office of Laboratory Animal Welfare (OLAW) number of A3572-01 provided by the National Institutes of Health (NIH). Animals are housed in a state-of-the-art ABL-3 facility that full-time staff veterinarians and support staff supervise. The CSU animal assurance welfare number is A3572-01 and is on file with the NIH. Veterinary care follows the American Veterinary Medical Association (AVMA) Guidelines. Animals were euthanized using CO2 asphyxiation with cervical dislocation for confirmation. This work was done using CSU Institutional Animal Care and Use Committee (IACUC) protocol 5172.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"462"}}